<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02282215</url>
  </required_header>
  <id_info>
    <org_study_id>CLT008-03</org_study_id>
    <nct_id>NCT02282215</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Human Myeloid Progenitor Cells (CLT-008) During Chemotherapy for Acute Myeloid Leukemia</brief_title>
  <official_title>An Open-Label Phase 2 Prospective, Randomized, Controlled Study of CLT-008 Myeloid Progenitor Cells as a Supportive Care Measure During Induction Chemotherapy for Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cellerant Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Department of Health and Human Services</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Cellerant Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to explore the safety and efficacy of CLT-008 as an extra
      supportive care measure after induction chemotherapy for patients with acute myeloid leukemia
      (AML).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The prolonged period of severe neutropenia caused by induction chemotherapy for the treatment
      of AML is associated with a nearly universal risk of febrile neutropenia. Standard supportive
      care strategies include administration of prophylactic anti-bacterial and anti-fungal agents,
      but serious breakthrough bacterial and fungal infections still occur. Granulocyte
      colony-stimulating factor (G-CSF; filgrastim, Neupogen®) has been shown to shorten the
      duration of severe neutropenia, fever, antibiotic use and hospitalization following induction
      chemotherapy for AML. CLT-008, a human allogeneic myeloid progenitor cell product, is
      intended to provide the cellular target for G-CSF to produce neutrophils during the period of
      chemotherapy-induced bone marrow suppression when the patient's own progenitor cells may be
      limited in responding to G-CSF. It is hypothesized that the production of allogeneic
      neutrophils from CLT-008 will be sufficient to mitigate the infection-related consequences of
      induction chemotherapy for AML.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2014</start_date>
  <completion_date type="Actual">September 22, 2017</completion_date>
  <primary_completion_date type="Actual">September 22, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of febrile episodes (fever)</measure>
    <time_frame>42 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to absolute neutrophil count (ANC) recovery</measure>
    <time_frame>42 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and duration of febrile neutropenia</measure>
    <time_frame>42 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and duration of infection</measure>
    <time_frame>42 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of mucositis</measure>
    <time_frame>42 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of infusion reactions</measure>
    <time_frame>42 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Graft-versus-Host Disease (GVHD)</measure>
    <time_frame>42 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events (AE)</measure>
    <time_frame>42 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Serious Adverse Events (SAE)</measure>
    <time_frame>42 days</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">163</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>CLT-008 low dose with G-CSF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CLT-008 high dose with G-CSF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CLT-008 with G-CSF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Randomized</description>
  </arm_group>
  <arm_group>
    <arm_group_label>G-CSF</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Randomized</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CLT-008</intervention_name>
    <description>Single intravenous infusion</description>
    <arm_group_label>CLT-008 low dose with G-CSF</arm_group_label>
    <arm_group_label>CLT-008 high dose with G-CSF</arm_group_label>
    <arm_group_label>CLT-008 with G-CSF</arm_group_label>
    <other_name>human allogeneic myeloid progenitor cells (hMPC)</other_name>
    <other_name>romyelocel-L</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>G-CSF</intervention_name>
    <description>Daily subcutaneous injections</description>
    <arm_group_label>CLT-008 low dose with G-CSF</arm_group_label>
    <arm_group_label>CLT-008 high dose with G-CSF</arm_group_label>
    <arm_group_label>CLT-008 with G-CSF</arm_group_label>
    <arm_group_label>G-CSF</arm_group_label>
    <other_name>Neupogen (filgrastim)</other_name>
    <other_name>granulocyte colony-stimulating factor</other_name>
    <other_name>Zarxio</other_name>
    <other_name>Granix (tbo-filgrastim)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Acute myeloid leukemia arising de novo (per European LeukemiaNet)

          2. Treated with any established chemotherapy regimen based on either:

               1. 7+3: Standard-dose cytarabine 100-200 mg per meter squared continuous infusion
                  for 7 days with idarubicin 12 mg per meter squared or daunarubicin 45-90 mg per
                  meter squared for 3 days

               2. High-dose cytarabine-based (HIDAC) chemotherapy administering a total cytarabine
                  dose of ≥ 4 g per meter squared alone or in combination with other anti-leukemic
                  agents (for example, anthracyclines, purine nucleoside inhibitors, etoposide,
                  etc.)

          3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 at Screening or by
             the day chemotherapy is initiated

          4. Adequate respiratory function with a room air oxygen saturation of at least 92%

          5. Adequate cardiac function defined as an ejection fraction of at least 45%

          6. Serum bilirubin ≤ 1.5 times the upper limits of normal. Subjects with a history of
             Gilbert's syndrome may be enrolled if the total bilirubin is &lt; 3 mg/dL with an
             indirect bilirubin of &gt; 1.5 mg/dL

          7. Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 times
             upper limits of normal prior to chemotherapy

          8. Serum creatinine ≤ 2 times upper limits of normal or estimated glomerular filtration
             rate ≥ 60 mL/min/1.73 meter squared per Modification of Diet in Renal Disease equation
             (MDRD)

          9. All subjects, except post-menopausal women, must be willing to utilize a highly
             effective method of contraception throughout the study

         10. Adequately informed of the nature and risks of the study with written informed consent

        Exclusion Criteria:

          1. Pregnant or breast feeding

          2. Overt central nervous system manifestations of leukemia at diagnosis

          3. Specifically diagnosed and uncontrolled fungal, bacterial, viral, or other infection
             (e.g. confirmed sepsis, pneumonia, abscess, cellulitis, etc.) at the day chemotherapy
             is initiated. &quot;Uncontrolled&quot; is defined as exhibiting ongoing signs and symptoms of
             infection without improvement despite antimicrobial or other treatment.

          4. AML subtype M3 (promyelocytic leukemia)

          5. Previous chemotherapy for AML

          6. History of or current human immunodeficiency virus (HIV) or hepatitis C virus
             infection

          7. History of or current clinically significant immunodeficiency

          8. Known contraindication to receiving G-CSF

          9. History of or current clinically significant alloimmunization to leukocyte antigens

         10. Participation in another clinical study within 28 days of the day chemotherapy is
             initiated, in which the study drug or device may influence hematopoiesis.
             Co-enrollment in another study is allowed in cases where the investigational therapy
             under study is a version of an acceptable chemotherapy regimen for this study per the
             inclusion criteria.

         11. Receiving any agent concurrently with CLT-008 infusion which inhibits cell division
             (e.g., methotrexate or hydroxyurea)

         12. Acute or chronic medical disorder that, in the opinion of the investigator or medical
             monitor, may prevent the subject from completing participation in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Reed, MD</last_name>
    <role>Study Director</role>
    <affiliation>Cellerant Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California San Diego Moores Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ronald Reagan UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UF Health Shands Cancer Hospital</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northside Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern Medical Faculty Foundation</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Illinois Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana Blood and Marrow Transplantation Clinic</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Massachusetts Worcester</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota Physicians BMT Clinic</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansas City Veterans Affairs Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College - New York Presbyterian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>66215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westchester Medical Center</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <zip>10595</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Penn Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Cancer Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.cellerant.com/pipeline/clt-008-myeloid-progenitor-cells.html</url>
    <description>Cellerant Therapeutics CLT-008: Myeloid Progenitor Cells</description>
  </link>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 31, 2014</study_first_submitted>
  <study_first_submitted_qc>October 31, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2014</study_first_posted>
  <last_update_submitted>November 15, 2017</last_update_submitted>
  <last_update_submitted_qc>November 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fever</keyword>
  <keyword>Induction chemotherapy</keyword>
  <keyword>Infection</keyword>
  <keyword>Leukemia</keyword>
  <keyword>Myeloid progenitor cells</keyword>
  <keyword>Neutropenia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

